Allogene Therapeutics receives $15M grant from CIRM for Phase 1 TRAVERSE trial of ALLO-316 CAR-T for metastatic renal cell carcinoma.
Allogene Therapeutics receives a $15M grant from California Institute for Regenerative Medicine (CIRM) to support clinical development of ALLO-316, an allogeneic CAR-T product targeting CD70 for metastatic renal cell carcinoma. The grant supports the Phase 1 TRAVERSE trial, which aims to evaluate the product's safety and efficacy in patients with advanced or metastatic renal cell carcinoma.
April 26, 2024
3 Articles